ArticleFrontiers in oncology2026
Case Report: Somatic
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurofibromatosis type 1 (NF1) and vestibular schwannoma are genetically and clinically distinct entities, with vestibular schwannomas classically associated with neurofibromatosis type 2. The occurrence of a vestibular schwannoma in a patient with NF1 is rare, and its underlying molecular mechanism remains unclear. Case presentation: We report a 51-year-old man clinically diagnosed with neurofibromatosis type 1 who developed a unilateral vestibular schwannoma presenting with progressive hearing loss and neurological symptoms. Histopathological examination following surgical resection confirmed the diagnosis of vestibular schwannoma, and genetic analyses were subsequently performed on the schwannoma, a cutaneous neurofibroma, and peripheral blood from the same patient. Genetic findings: Whole-exome sequencing revealed a pathogenic germline NF1 mutation shared across all analyzed samples. In contrast, the vestibular schwannoma harbored a somatic NF2 mutation accompanied by loss of chromosome 22, while these alterations were absent in the neurofibroma and blood samples. Conclusion: This case demonstrates that a vestibular schwannoma arising in a patient with neurofibromatosis type 1 can be driven by secondary somatic NF2 alterations accompanied by loss of chromosome 22. Comprehensive multi-tissue genetic analysis enabled direct distinction between germline and tumor-specific events, highlighting the critical role of tumor-specific somatic alterations beyond the germline background.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.